Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance
Abstract
1. Introduction
2. Latent Tuberculosis Infection
3. Contact Assessment and Testing
4. Migration
5. Catastrophic Costs and Financial Burden
6. Healthcare Workers
7. Conclusions
Funding
Conflicts of Interest
References
- World Health Organization. Ethics Guidance for the Implementation of the End TB Strategy; World Health Organization: Geneva, Switzerland, 2017. [Google Scholar]
- Denholm, J.; Matteelli, A.; Reis, A. Latent tuberculous infection: Ethical considerations in formulating public health policy. Int. J. Tuberc. Lung Dis. 2015, 19, 137–140. [Google Scholar] [CrossRef] [PubMed]
- Sterling, T.R.; Villarino, M.E.; Borisov, A.S.; Shang, N.; Gordin, F.; Bliven-Sizemore, E.; Hackman, J.; Hamilton, C.D.; Menzies, D.; Kerrigan, A.; et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. N. Engl. J. Med. 2011, 365, 2155–2166. [Google Scholar] [CrossRef] [PubMed]
- Menzies, D.; Adjobimey, M.; Ruslami, R.; Trajman, A.; Sow, O.; Kim, H.; Obeng Baah, J.; Marks, G.B.; Long, R.; Hoeppner, V.; et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N. Engl. J. Med. 2018, 379, 440–453. [Google Scholar] [CrossRef] [PubMed]
- DeLuca, A.; Frick, M.; Lessem, E.; Kanouse, J.; Wegener, D.; Mingote, L.R. Activism on rifapentine pricing: Removing cost barriers to improve the uptake of tuberculosis research innovations. Public Health Action 2014, 4, 238–242. [Google Scholar] [CrossRef] [PubMed]
- Denholm, J.T.; McBryde, E.S.; Eisen, D.; Street, A.; Matchett, E.; Chen, C.; Shultz, T.; Biggs, B.; Leder, K. SIRCLE: A randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication. Intern. Med. J. 2017, 47, 1433–1436. [Google Scholar] [CrossRef] [PubMed]
- Belknap, R.; Borisov, A.; Holland, D. Adherence to Once-Weekly Self-Administered INH and Rifapentine for Latent TB: IAdhere. In Proceedings of the Conference on Retroviruses and Opportunistic Infections Seattle, Washington, DC, USA, 23–26 February 2015. [Google Scholar]
- Lee, S.Y.; Lee, K.A.; Ki, C.S.; Kwon, O.J.; Kim, H.J.; Chung, M.P.; Suh, G.Y.; Kim, J.W. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin. Chem. 2002, 48, 775–777. [Google Scholar] [PubMed]
- Ellard, G. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol. Ther. 1976, 19, 610–625. [Google Scholar] [CrossRef] [PubMed]
- Ott, J.J.; Stevens, G.A.; Groeger, J.; Wiersma, S.T. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30, 2212–2219. [Google Scholar] [CrossRef] [PubMed]
- Guariguata, L.; Whiting, D.R.; Hambleton, I.; Beagley, J.; Linnenkamp, U.; Shaw, J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 2014, 103, 137–149. [Google Scholar] [CrossRef] [PubMed]
- Snow, K.J.; Sismanidis, C.; Denholm, J.; Sawyer, S.M.; Graham, S.M. The incidence of tuberculosis among adolescents and young adults: A global estimate. Eur. Respir. J. 2018, 51, 1702352. [Google Scholar] [CrossRef] [PubMed]
- Fox, G.J.; Dobler, C.C.; Marais, B.J.; Denholm, J.T. Preventive therapy for latent tuberculosis infection—The promise and the challenges. Int. J. Infect. Dis. 2017, 56, 68–76. [Google Scholar] [CrossRef] [PubMed]
- Marks, S.M.; Mase, S.R.; Morris, S.B. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin. Infect. Dis. 2017, 64, 1670–1677. [Google Scholar] [CrossRef] [PubMed]
- Ragonnet, R.; Trauer, J.M.; McBryde, E.S.; Houben, R.M.; Denholm, J.T.; Handel, A.; Sumner, T. Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact. Int. J. Tuberc. Lung Dis. 2017, 21, 60–66. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Latent TB Infection: Updated and Consolidated Guidelines for Programmatic Management; World Health Organization: Geneva, Switzerland, 2018. [Google Scholar]
- Temprano ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N. Engl. J. Med. 2015, 373, 808–822. [Google Scholar] [CrossRef] [PubMed]
- United Nations. Trends in International Migrant Stock: Migrants by Destination and Origin. Available online: www.un.org/en/development/desa/population/migration/data/estimates2/estimates15.shtml (accessed on 10 October 2018).
- Elias, J. Governing Domestic Worker Migration in Southeast Asia: Public–Private Partnerships, Regulatory Grey Zones and the Household. J. Contemp. Asia 2018, 48, 278–300. [Google Scholar] [CrossRef]
- Piper, N.; Rosewarne, S.; Withers, M. Redefining a Rights-Based Approach in the Context of Temporary Labour Migration in Asia; UNRISD Working Paper 2016-11; UNRISD: Geneva, Switzerland, 2016. [Google Scholar]
- Lönnroth, K.; Migliori, G.B.; Abubakar, I.; D’Ambrosio, L.; De Vries, G.; Diel, R.; Douglas, P.; Falzon, D.; Gaudreau, M.A.; Goletti, D.; et al. Towards tuberculosis elimination: An action framework for low-incidence countries. Eur. Respir. J. 2015, 45, 928–952. [Google Scholar] [CrossRef] [PubMed]
- Von Delft, A.; Dramowski, A.; Khosa, C.; Kotze, K.; Lederer, P.; Mosidi, T.; Peters, J.A.; Smith, J.; van der Westhuizen, H.M.; von Delft, D.; et al. Why healthcare workers are sick of TB. Int. J. Infect.Dis. 2015, 32, 147–151. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Denholm, J.T.; Silva, D.S.; Burhan, E.; Chaisson, R.E. Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance. Trop. Med. Infect. Dis. 2018, 3, 115. https://doi.org/10.3390/tropicalmed3040115
Denholm JT, Silva DS, Burhan E, Chaisson RE. Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance. Tropical Medicine and Infectious Disease. 2018; 3(4):115. https://doi.org/10.3390/tropicalmed3040115
Chicago/Turabian StyleDenholm, Justin T., Diego S. Silva, Erlina Burhan, and Richard E. Chaisson. 2018. "Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance" Tropical Medicine and Infectious Disease 3, no. 4: 115. https://doi.org/10.3390/tropicalmed3040115
APA StyleDenholm, J. T., Silva, D. S., Burhan, E., & Chaisson, R. E. (2018). Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance. Tropical Medicine and Infectious Disease, 3(4), 115. https://doi.org/10.3390/tropicalmed3040115